Skip to main content
KalVista Pharmaceuticals, Inc logo
Menu toggle

Main navigation

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • Sebetralstat
    • Factor XIIa
    • KalVista for DME
    • Publications
  • For Patients
    • Clinical Studies
    • HAE Resources
    • Sebetralstat
    • Factor XIIa
    • DME Resources
  • For Healthcare Providers
    • HAE Resources
    • Sebetralstat
    • Factor XIIa
    • DME Resources
    • Publications
    • Expanded Access
  • For Investors
    • Stock Information
    • News Releases
    • Events Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance

Creating a new generation of small molecule protease inhibitors for HAE and DME

KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & …

Hereditary Angioedema (HAE)

Diabetic Macular Edema (DME)

Positive Phase 2 Data for Oral KVD900 in Hereditary Angioedema (HAE)

For more information, click here

Reduced use of rescue treatment for HAE attack

graph 1

Mild to moderate HAE attacks treated with Sebetralstat significantly reduced use of rescue (p=0.001), with 15% of Sebetralstat treated attacks rescued compared to 30% on placebo at 12 hours.

Reduced time to symptom relief on PGI-C scale

graph 2

Sebetralstat significantly reduced time to onset of symptom relief after HAE attacks on a Patient Global Impression of Change scale (PGI-C), with median time of 1.6 hours with Sebetralstat vs. 9 hours for with placebo (p=<0.0001).

Sustained cumulative symptom relief as assessed by VAS

clock

Cumulative symptom relief (defined as 50% reduction in composite VAS score for three consecutive time points) was maintained at 24 hours (p=0.0005) vs. placebo.

Sebetralstat is an investigational product candidate currently in clinical development as an oral on-demand therapy for HAE attacks.

News

Kalvista Pharmaceuticals

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

Mar 9, 2023
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting

Feb 27, 2023
Kalvista Pharmaceuticals

KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma &amp; Immunology

Feb 16, 2023
All News

Footer

  • About KalVista
  • Products & Pipeline
  • For Patients
  • For Healthcare Providers
  • For Investors
  • Contact Us
+1 (857) 999 0075 info@kalvista.com medinfo@kalvista.com

Social Menu

  • Linked In
  • Twitter
Copyright © 2023 | All rights reserved.

Footer Bottom

  • KalVista Terms
  • Privacy